Clinical Trials
19 trialsNCT01253070 2022-08-04
Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT01254578 2017-09-25
Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers
National Cancer Institute (NCI)
Phase 1 Completed
NCT00313586 2017-02-02
Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00062075 2015-12-04
Romidepsin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00588809 2015-08-05
Selumetinib in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00217646 2015-04-28
Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia
National Cancer Institute (NCI)
Phase 1 Completed
NCT00351975 2014-12-23
Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases
National Cancer Institute (NCI)
Phase 1 Completed
NCT01132586 2014-12-23
Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 1 Completed
NCT00305773 2014-05-19
Vorinostat in Treating Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00301938 2013-09-30
7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic Syndromes
National Cancer Institute (NCI)
Phase 1 Completed
NCT00331513 2013-09-30
Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndromes
National Cancer Institute (NCI)
Phase 1 Completed
NCT00006019 2013-06-24
Phenylbutyrate Plus Azacitidine in Treating Patients With Acute Myeloid Leukemia, Myelodysplasia, Non-Hodgkin's Lymphoma, Multiple Myeloma, Non-small Cell Lung Cancer, or Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00006223 2013-06-24
flt3L in Treating Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 3 Completed
NCT00003934 2013-06-05
Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic Leukemia
National Cancer Institute (NCI)
Phase 3 Completed
NCT00357305 2013-05-03
Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders
National Cancer Institute (NCI)
Phase 1 Completed
NCT00114257 2013-02-11
Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders
National Cancer Institute (NCI)
Phase 1 Completed
NCT00005064 2013-01-23
PS-341 in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia in Blast Phase, or Myelodysplastic Syndrome
National Cancer Institute (NCI)
Phase 1 Completed
NCT00006213 2013-01-23
BMS-214662 in Treating Patients With Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myeloid Leukemia
National Cancer Institute (NCI)
Phase 1 Completed
NCT00098826 2013-01-11
SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromes
National Cancer Institute (NCI)
Phase 1 Completed